OP-ED: Coronavirus: How a Rational CDC Scientist Would

New Post Public Reply Private Reply Replies (1) Message Board
wowhappens28
190
OP-ED: Coronavirus: How a Rational CDC Scientist Would Think, if One Existed

https://www.greenmedinfo.com/blog/op-ed-coron...ne-existed

OP-ED by Jon Rappoport

In a recent article, I explained why the diagnostic test for the coronavirus in a patient is worthless and unreliable. The implications of that fact are enormous.

Here, I want to make further comments on fake science.

A rational researcher, at the CDC, if one existed, would say, upon hearing of a possible outbreak in the city of Wuhan: "Let's see the proof that a new virus is responsible, is the causative agent."

What kind of proof would he be asking for?

First, he would want to know, "Do researchers there have an actual biological specimen of this new virus? Do they have the real thing?"

And if the answer came back yes, he would reply, "We're sending in one of our Wuhan people so he can confirm that."

But how would the confirmation work? You can't just lay a specimen of a virus on a table and shine a light on it. It's far too small to see.

There is a traditional method of observation. It's called an electron microscope photograph (an EM). Certain established procedures exist for obtaining an EM from a patient's tissue sample. The CDC scientist would want to make sure the Chinese scientists had carried out this process correctly.

He would say, "Let's have a look at the Chinese EM." He wants to confirm there are many identical particles of the new virus in the EM. Let's buck the odds and imagine he does confirm it. So far, so good.

But there is more. And here is where the rubber meets the road and the failure factor is very high. I need to back up a bit to explain.

When a clinical trial of a new drug is done (and here I'll make a gigantic leap and assume it's done correctly), is it carried out on one patient?

Is the result of giving the drug to a single patient then extrapolated to mean everyone will react the way this one person did? Of course not. That would be absurd. In a clinical trial, sooner or later, researchers are dealing with a large number of volunteers. A thousand or more.

So, in the case of a new coronavirus, in China, the rational CDC scientist would say: "I want to see electron microscope photographs derived from five hundred patients who have been provisionally diagnosed with the new disease."

I myself ask, where are these photographs? Where are the completely necessary photographs? Because the Chinese scientist would tell his CDC counterpart, "Oh, we didn't carry out the EM procedure on five hundred patients. We carried it out on one. Two. Maybe three. I'm not sure."

At which point, this fantasy rational CDC scientist would blow his stack. He would say, "You're declaring a new epidemic based on two or three photographs from two or three patients??"

Of course, I would need rock solid proof that, at the CDC, there is a rational scientist who would ask for EM pictures from five hundred patients, and explode if he couldn't find them because they were never done. Show me such a rational CDC scientist. Bring him forward. I want to interview him. I want to find out how he feels being ostracized by every other scientist at the CDC.

Consider this likely scenario---which explains why researchers only did the EMs on two or three of the patients. If someone actually performed the electron microscope work on 500 patients diagnosed with the new disease, he would find some indication, in the photographs, of a coronavirus in maybe nine patients.

At which point, in Wuhan, they would shrug and say, "Well, wow, that didn't work out. What a flop. Our hypothesis of a new disease based on a new coronavirus collapsed. We should have been able to see lots of the virus in the photos from ALL 500 patients, or at least the overwhelming percentage of the 500. And we didn't. Back to the drawing board. Let's see. What's the primary sign of the new disease? Pneumonia? Come to think of it, about 300,000 people in China die of pneumonia every year. How about we look at some studies on the air quality here in Wuhan? I think my colleague down the block has a pile of them. Let's walk over there. Anybody have a searchlight so we can see the street through the fog of pollution? Let me get my oxygen tank and breathing helmet."

And that would be the end of that.

Back in Atlanta, the rational CDC scientist would say to his colleagues, "That Chinese outbreak wasn't a virus. How about we spend the afternoon going through some of our own studies on vaccines? I know the fraud is rampant. Let's get it out in the open."

Sure. Happens every day over at the CDC.

Of course, I could be wrong. Maybe someone has done electron microscope photographs derived from 500 patients diagnosed with the new epidemic disease. LET'S SEE THE PHOTOS. SHOW THEM TO ME. We'll have a few non-conflicted experts analyze them.

Otherwise, don't talk about science. There is no science going on.
Scroll down for more posts ▼

Top 10 Most Recent News Articles

Lear Corporation Talks Future at Morgan Stanley Conference

Updated Category News Views 7

Why the Chatter at Laguna Conference Matters Alright folks, here's the scoop that the suits over at Lear are gearing up for: a fireside chat at the Morgan Stanley 14th Annual Laguna Conference. At first glance, you might shrug and say, "Big deal." But what's a conference worth if not to attract a bit of investor buzz, right? With Ray Scott, the President and CEO, and...

Continue Reading
Eosera Defies Odds with Texas-Made Ear Care Dominance

Updated Category News Views 0

Who would've thought an ear care outfit outta Fort Worth could snag a spot on the Inc. 5000 list for six years running? That's right, eosera® is hanging tough, even while the industry's been in a tailspin and tariffs have been squeezing everyone’s margins. Pushing Through Tough Terrain The ear care sector isn't exactly the first place investors look for a splash,...

Continue Reading
ePlus Wins Big: First Ambassador Partner for Everpure

Updated Category News Views 1

ePlus Breaks Ground with Everpure There's a new chapter unfolding in the tech sector, and ePlus has carved its name on the marquee. Achieving the exclusive Ambassador Partner Status with Everpure, ePlus becomes the first in North America to hit this high note. In the crowded room of tech partnerships, this isn't just a pat on the back—it's a gold star that screams...

Continue Reading
Flotek Faces Lawsuit: Investors Urged to Act Fast

Updated Category News Views 3

Flotek's Current Storm: Gather Your Wits, Shareholders If you've staked your hard-earned cash into Flotek Industries, Inc. (FTK), it's high time to buckle up. Those court-blaring sirens aren’t a drill: we're talking class-action territory, people. The Law Offices of Howard G. Smith sound the alarm, calling on investors who’ve had their financial feathers singed to...

Continue Reading
Ecobat's Strategic Shift: Exiting Lithium for Lead

Updated Category News Views 5

You ever get that sense of déjà vu when another company decides to jump ship from a supposedly hot market? Well, that's where Ecobat's at, folks. This global player in battery recycling just waved goodbye to its lithium recycling biz, closing the deal on its Arizona operations. Previously, they ditched similar holdings in the UK and Germany. Now, they're all-in on their...

Continue Reading
AEC Firms Revamp Strategies Amid Talent Tug-of-War

Updated Category News Views 3

The State of Compensation in AEC Sit back and chew on this—AEC firms are playing a whole new ball game when it comes to compensating their talent. FMI Corporation’s 2026 Compensation Trends Study is putting a spotlight on what really goes on behind the scenes in architecture, engineering, and construction firms. This is about more than just tossing some coin for a...

Continue Reading
Scrutinizing GPRO and VCTR Deals for Shareholders

Updated Category News Views 0

GoPro and Victory Capital: Fair Play or Foul? Ah, mergers and acquisitions—the high-stakes poker game of the corporate world. These days, GoPro (NASDAQ:GPRO) and Victory Capital (NASDAQ:VCTR) find themselves right in the thick of things. Now, I’ve seen enough corporate chess games to know when to raise an eyebrow, and folks, that's exactly what's happening here. The...

Continue Reading
Opus Group Revamps Turkish Vehicle Inspection System

Updated Category News Views 1

Leveraging Expertise in Vehicle Inspection Opus Group is gearing up to revolutionize the vehicle inspection landscape in Türkiye. With a staggering 34.5 million vehicles on the roads, and an annual inspection quota hitting 16 million, the market is ripe for innovation. The U.S.-based Opus Group, a giant in the realm of vehicle inspection programs with about 30 million...

Continue Reading
PMI Foods Fuels Hunger Action Month with New Partnership

Updated Category News Views 3

Helping Families Put Food on the Table Out there in Utah's schoolyards, Parker Migliorini International (PMI Foods) is taking a tangible step against hunger, whipping out a $15,000 check to back the Utah Food Bank’s Mobile School Pantry initiative. This partnership kicks off in September, aligning with Hunger Action Month, a period dedicated to spotlighting food...

Continue Reading
Shell Seals ARC Acquisition, $16.5B Bet on Future

Updated Category News Views 3

Shell’s Strategic Play: Snagging ARC When it comes to Shell, they don't dawdle with peanuts. Snagging ARC Resources Ltd., a Canadian energy firm rooted squarely in British Columbia and Alberta, speaks volumes about their appetite for growth. They’re shelling out approximately US$16.5 billion to pull this deal off the ground. This isn't just some casual sector play; it...

Continue Reading

Top 5 Most Recently Viewed Articles

Sonia Scarselli Joins Endeavour Mining as EVP of Exploration

Updated Category News Views 328

Endeavour Mining Elevates Sonia Scarselli to Executive Vice President Sonia Scarselli has been appointed as the Executive Vice President (EVP) of Exploration at Endeavour Mining plc, a notable milestone in her career and an exciting new chapter for Endeavour. Coming from a prestigious background with BHP, she is set to take on this critical role starting December 2024....

Continue Reading
Lithium Industries in Flux: Insights on Market Dynamics

Updated Category News Views 179

Geopolitical Influence on Lithium Markets Lithium investors were recently reminded that market dynamics can shift dramatically due to geopolitical events. After experiencing a vibrant rally supported by retail enthusiasm, Lithium Americas Corp. (NYSE:LAC) noticed a significant decline of 45% within just a month. This downturn can be traced back to changing dialogues...

Continue Reading
How Flex Ltd's AI Innovations Are Shaping Its Market Strategy

Updated Category News Views 447

Flex Ltd: Innovating Through AI Technologies Flex Ltd (NASDAQ: FLEX) is making waves in the IT Hardware and Communications Equipment industry. Known for its strategic growth potential, the company is attracting investor interest as it adapts to the fast-paced technological landscape. With significant advancements in AI and cloud computing, Flex is positioning itself for...

Continue Reading
Exploring the Rapid Growth of Advanced Biofuels Market Trends

Updated Category News Views 123

The Growth of the Advanced Biofuels Market As global energy demands evolve, the advanced biofuels market is set to experience remarkable growth. Projections indicate a shift from an estimated market size of USD 20.1 billion in the near future to a staggering USD 45.8 billion within a decade. This rapid expansion translates to a compound annual growth rate (CAGR) of 8.6%,...

Continue Reading
Legal Insights for Backblaze Investors Facing Claims Unveiled

Updated Category News Views 226

Understanding the Current Situation for Backblaze, Inc. Investors Investors of Backblaze, Inc. (NASDAQ: BLZE) are currently under close scrutiny due to an ongoing investigation regarding potential securities class action claims. This situation stems from serious allegations that the company might have provided misleading information that could affect investor decisions...

Continue Reading